Case 5: Discussion
Persistently Low CD4 Counts in Patients with Suppressed HIV RNA
Among patients who take antiretroviral therapy and achieve suppression of HIV RNA levels, most have a substantial increase in their CD4 cell count. Typically, patients have a brisk increase in CD4 cells in the first 3 to 6 months after starting antiretroviral therapy, predominantly due to a release of memory CD4 cells trapped within lymphoid tissue. In the second phase of CD4 recovery, there is a gradual increase in CD4 counts that continues for 3 to 6 years; this phase involves both naive CD4 cells (from the thymus) and memory CD4 cells. Approximately one-third of patients who maintain continuous suppression of HIV do not recover their CD4 cell count to a level above 500 cells/mm3 after 5 years. A smaller proportion of patients (less than 10%) fail to recover their CD4 count at a level greater than 200 cells/mm3 despite virologic suppression. This is often referred to as a "discordant" or " immuno-virological discordant" response (good virologic response and poor immunologic recovery). This discordant response is associated with increased risk for developing an opportunistic infection and increased progression to AIDS or death[3,4,5,6], but the risk of developing new AIDS-defining event declines substantially after the first 6 months of virologic suppression. "Discordant responses" can also refer to good immunologic responses despite incomplete virologic suppression, but the following discussion will not address this issue.
Immunologic Recovery Based on Specific Antiretroviral Regimens
Most patients who achieve sustained virologic suppression with one of the recommended modern antiretroviral therapy regimens have good CD4 count recovery. Existing data suggest that in antiretroviral-naive patients, efavirenz (Sustiva) produces lower CD4 cell count recovery than with boosted-protease inhibitors, maraviroc (Selzentry), and raltegravir (Isentress). In ACTG 5142, patients receiving lopinavir-ritonavir plus two nucleoside reverse transcriptase inhibitors (NRTIs) had greater CD4 cell count increases at 96 weeks than patients taking efavirenz plus two NRTIs (287 versus 230 cells/mm3). A meta-analysis reported that mean CD4 cell count increases at week 48 were better with a ritonavir-boosted protease inhibitor regimen (+200 cells/mm3) than a non-boosted protease inhibitor regimen (+179 cells/mm3) or a non-nucleoside reverse transcriptase inhibitor (NNRTI)-based regimen (+173 cells/mm3) (Figure 1). This meta-analysis, however, had multiple confounding factors, and the NNRTI-based regimens included data for nevirapine. Analysis of the Swiss HIV Cohort study also showed a trend for better CD4 responses with boosted-protease inhibitor regimens (Figure 2). Similar CD4 cell count recovery occurs with most, but not all, NRTIs. The combination of tenofovir (Viread) and didanosine (Videx) has been associated with lower CD4 cell count responses, particularly when the didanosine dose exceeds 4.1 mg/kg (Figure 3). In addition, zidovudine-based regimens may have poorer CD4 count responses, presumably because of the marrow suppressive effect of zidovudine.
Causes of Discordant Responses with Poor Immunologic Recovery
When patients have poor CD4 cell count responses in the setting of sustained virologic suppression, several potential reversible causes should be considered, including receipt of marrow-suppressive medications and infiltrative bone marrow processes. Common marrow suppressive drugs used in HIV-infected patients include zidovudine (Retrovir) and zidovudine containing fixed combination pills (Combivir, Trizivir), trimethoprim-sulfamethoxazole (Bactrim, Septra), interferon and peg-interferon preparations, pyrimethamine, sulfadiazine, ganciclovir, valganciclovir, and etoposide. Medication-related marrow suppression is more likely to occur when a combination of marrow suppressive agents are used, such as zidovudine plus trimethoprim-sulfamethoxazole. Marrow infiltrative processes, such as lymphoma and disseminated histoplasmosis, should also be considered. Only after excluding reversible causes of poor immunologic should the patient be considered to have a true discordant response with poor immunologic recovery. Factors identified with poor immunologic recovery include low baseline CD4 cell count[14,15,16], older age, and possibly co-infection with hepatitis C virus.
Interleukin-2 for Persistently Low CD4 Cell Counts
Several studies clearly established that interleukin-2 given with antiretroviral therapy causes substantially greater increases in CD4 cell counts than antiretroviral therapy alone. In contrast, interleukin-2 given without antiretroviral therapy generates inferior CD4 count responses when compared with antiretroviral therapy alone. These interleukin-2 studies, while showing good CD4 cell count increases, did not evaluate whether the interleukin-2 induced-CD4 cell counts translated into clinical benefit. Patients who have a discordant response and CD4 counts persistently less than 200 cells/mm3 are of particular interest for potential therapeutic measures, such as interleukin-2, that could substantially increase CD4 counts. Specifically, the hope has been that patients with sustained virologic suppression but poor immunologic recovery could substantially increase their CD4 cell count using interleukin-2, thereby reducing their risk of opportunistic infection and death. To determine whether the addition of interleukin-2 to antiretroviral therapy reduced the risk of opportunistic diseases or death, the NIH sponsored two large phase 3, randomized, international trials: (1) Evaluation of Subcutaneous Proleukin in a Randomized International Trial (ESPRIT), and (2) Subcutaneous Recombinant Human IL-2 in HIV-infected Patients with Low CD4 Counts under Active Antiretroviral Therapy (SILCAAT). In ESPRIT, 4,111 patients with a CD4 cell count greater than 350 cells/mm3 were randomized to receive interleukin-2 (Proleukin) plus antiretroviral therapy or antiretroviral therapy alone; interleukin-2 was given at a dose of 7.5 MIU twice daily for 5 consecutive days every 8 weeks for at least 6 months, and patients had an average follow-up of 7 years. Although patients who received interleukin-2 and antiretroviral therapy had an average CD4 count 159 cells/mm3 greater than those who received antiretroviral therapy alone, there was no difference in clinical outcomes (Figure 4). Investigators in SILCAAT randomized 1,695 patients with a CD4 cell count between 50 and 299 cells/mm3 to receive interleukin-2 plus antiretroviral therapy or antiretroviral therapy alone, with follow-up of approximately 7 years. Interleukin-2 was given at a dose of 4.5 MIU twice daily for 5 consecutive days every 8 weeks for 49 weeks. Patients who received interleukin-2 and antiretroviral therapy had an average CD4 count 53 cells/mm3 greater than those who received antiretroviral therapy alone, but no differences in clinical outcomes were observed (Figure 5). The reason for the lack of clinical benefit despite increased CD4 counts remains unclear.
Recommendations for Patients with Persistently Low CD4 Cell Counts
For persons who have sustained virologic suppression for at least 2 years but have CD4 counts consistently less than 200 cells/mm3, the following approach is recommended. First, make certain the patient is receiving appropriate prophylaxis for opportunistic infections. Second, examine the patient's medication list for medications that can suppress bone marrow. In patients taking a potentially marrow suppressive drug, change the medication to a non-marrow suppressive drug, if possible. For example, consider switching from a zidovudine-containing regimen to a regimen that does not contain zidovudine. Third, evaluate the patient for clinical manifestations, such as systemic symptoms or pancytopenia, which suggest a marrow infiltrative process. Fourth, continue antiretroviral therapy, even if the patient has not had a good CD4 cell count response. Multiple studies have shown that achieving a durable virologic response translates into clinical benefit independent of CD4 count. There are no "switch" data that support a change from one suppressive regimen to another, although the combination of tenofovir plus didanosine (especially at full dose) should be avoided, and there may be potential benefit of switching to a non-zidovudine-containing regimen. There is evidence, discussed above, that regimens containing ritonavir-boosted protease inhibitors, maraviroc, and raltegravir result in greater CD4 cell count responses than efavirenz-based regimens, although there is currently little evidence supporting modification or intensification of efavirenz-based regimens in patients with discordant CD4 responses. The intensification approach is currently being evaluated in clinical trials. Finally, existing data do not support the use of interleukin-2 in this setting. Although preliminary data with other investigational agents, such as interleukin-7, have demonstrated an increase in CD4 cell counts, there are no clinical data to support the use of such therapies in clinical practice.
1 Battegay M, N�esch R, Hirschel B, Kaufmann GR. Immunological recovery and antiretroviral therapy in HIV-1 infection. Lancet Infect Dis. 2006;6:280-7.PubMed Abstract
2 Egger M, Hirschel B, Francioli P, et al. Impact of new antiretroviral combination therapies in HIV infected patients in Switzerland: prospective multicentre study. Swiss HIV Cohort Study. BMJ. 1997;315:1194-9.PubMed Abstract
3 Grabar S, Le Moing V, Goujard C, Leport C, Kazatchkine MD, Costagliola D, Weiss L. Clinical outcome of patients with HIV-1 infection according to immunologic and virologic response after 6 months of highly active antiretroviral therapy. Ann Intern Med. 2000;133:401-10.PubMed Abstract
4 Tan R, Westfall AO, Willig JH, Mugavero MJ, Saag MS, Kaslow RA, Kempf MC. Clinical outcome of HIV-infected antiretroviral-naive patients with discordant immunologic and virologic responses to highly active antiretroviral therapy. J Acquir Immune Defic Syndr. 2008;47:553-8.PubMed Abstract
5 Human immunodeficiency virus type 1 RNA level and CD4 count as prognostic markers and surrogate end points: a meta-analysis. HIV Surrogate Marker Collaborative Group. AIDS Res Hum Retroviruses. 2000;16:1123-33.PubMed Abstract
6 Zoufaly A, an der Heiden M, Kollan C, Bogner JR, et al. Clinical outcome of HIV-infected patients with discordant virological and immunological response to antiretroviral therapy. J Infect Dis. 2011;203:364-71.PubMed Abstract
7 Riddler SA, Haubrich R, DiRienzo AG, et al. Class-sparing regimens for initial treatment of HIV-1 infection. N Engl J Med. 2008;358:2095-106.PubMed Abstract
8 Sierra-Madero J, Di Perri G, Wood R, et al. Efficacy and safety of maraviroc versus efavirenz, both with zidovudine/lamivudine: 96-week results from the MERIT study. HIV Clin Trials. 2010;11:125-32.PubMed Abstract
9 Lennox JL, Dejesus E, Lazzarin A, et al. Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial. Lancet. 2009;374(9692):796-806.PubMed Abstract
10 Bartlett JA, Fath MJ, Demasi R, Hermes A, Quinn J, Mondou E, Rousseau F. An updated systematic overview of triple combination therapy in antiretroviral-naive HIV-infected adults. AIDS. 2006;20:2051-64. PubMed Abstract
11 Khanna N, Opravil M, Furrer H, Cavassini M, Vernazza P, Bernasconi E, Weber R, Hirschel B, Battegay M, Kaufmann GR; Swiss HIV Cohort Study. CD4+ T cell count recovery in HIV type 1-infected patients is independent of class of antiretroviral therapy. Clin Infect Dis. 2008;47:1093-101. PubMed Abstract
12 Karrer U, Ledergerber B, Furrer H, et al. Dose-dependent influence of didanosine on immune recovery in HIV-infected patients treated with tenofovir. AIDS. 2005;19:1987-94.PubMed Abstract
13 Gallant JE, DeJesus E, Arribas JR, et al. Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV. N Engl J Med. 2006;354:251-60.PubMed Abstract
14 Gras L, Kesselring AM, Griffin JT, et al. CD4 cell counts of 800 cells/mm3 or greater after 7 years of highly active antiretroviral therapy are feasible in most patients starting with 350 cells/mm3 or greater. J Acquir Immune Defic Syndr. 2007;45:183-92.PubMed Abstract
15 Moore RD, Keruly JC. CD4+ cell count 6 years after commencement of highly active antiretroviral therapy in persons with sustained virologic suppression. Clin Infect Dis. 2007;44:441-6.PubMed Abstract
16 Kelley CF, Kitchen CM, Hunt PW, Rodriguez B, Hecht FM, Kitahata M, Crane HM, Willig J, Mugavero M, Saag M, Martin JN, Deeks SG. Incomplete peripheral CD4+ cell count restoration in HIV-infected patients receiving long-term antiretroviral treatment. Clin Infect Dis. 2009;48:787-94.PubMed Abstract
17 Kaufmann GR, Bloch M, Finlayson R, Zaunders J, Smith D, Cooper DA. The extent of HIV-1-related immunodeficiency and age predict the long-term CD4 T lymphocyte response to potent antiretroviral therapy. AIDS. 2002;16:359-67. PubMed Abstract
18 Davey RT Jr, Murphy RL, Graziano FM, et al. Immunologic and virologic effects of subcutaneous interleukin 2 in combination with antiretroviral therapy: A randomized controlled trial. JAMA. 2000;284:183-9.PubMed Abstract
19 Porter BO, Anthony KB, Shen J, et al. Inferiority of IL-2 alone versus IL-2 with HAART in maintaining CD4 T cell counts during HAART interruption: a randomized controlled trial. AIDS. 2009;23:203-12.PubMed Abstract
20 INSIGHT-ESPRIT Study Group and SILCAAT Scientific Committee. Interleukin-2 therapy in patients with HIV infection. N Engl J Med. 2009;361:1548-59.PubMed Abstract
21 Kazanjian P, Wei W, Brown M, Gandhi T, Amin K. Viral load responses to HAART is an independent predictor of a new AIDS event in late stage HIV infected patients: prospective cohort study. J Transl Med. 2005;3:40. PubMed Abstract
22 Levy Y, Lacabaratz C, Weiss L, et al. Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J Clin Invest. 2009;119:997-1007.PubMed Abstract
Copyright © 2004-2013 University of Washington